5QTW
 
 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate | 分子名称: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | 著者 | Sheriff, S. | 登録日 | 2019-11-13 | 公開日 | 2020-01-29 | 最終更新日 | 2024-10-23 | 実験手法 | X-RAY DIFFRACTION (2.12 Å) | 主引用文献 | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa. Bioorg.Med.Chem.Lett., 30, 2020
|
|
5QTV
 
 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate | 分子名称: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | 著者 | Sheriff, S. | 登録日 | 2019-11-13 | 公開日 | 2020-01-29 | 最終更新日 | 2024-10-23 | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | 主引用文献 | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa. Bioorg.Med.Chem.Lett., 30, 2020
|
|
5QTX
 
 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecine-2-carboxylate | 分子名称: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | 著者 | Sheriff, S. | 登録日 | 2019-11-13 | 公開日 | 2020-01-29 | 最終更新日 | 2024-10-23 | 実験手法 | X-RAY DIFFRACTION (2.07 Å) | 主引用文献 | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa. Bioorg.Med.Chem.Lett., 30, 2020
|
|
5QTY
 
 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-15-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecine-2-carboxylate | 分子名称: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | 著者 | Sheriff, S. | 登録日 | 2019-11-13 | 公開日 | 2020-01-29 | 最終更新日 | 2024-10-16 | 実験手法 | X-RAY DIFFRACTION (1.89 Å) | 主引用文献 | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa. Bioorg.Med.Chem.Lett., 30, 2020
|
|
6NZF
 
 | |
6NZE
 
 | |
6NZH
 
 | |
6NZR
 
 | |
6NZP
 
 | |
6NZQ
 
 | |
7UZN
 
 | CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH BMT-206059 AKA 2-{(3M)-3-(1,4-DIMETHYL-1H-1,2,3-TRIAZOL-5-YL)-8-FLUORO-5-[(S)-(OXAN-4-YL)(PHENYL)METHYL]-5H-PYRIDO[3,2-b]INDOL-7-YL}PROPAN-2-OL, TRIPLY DEUTERATED ON THE 4-METHYL GROUP | 分子名称: | 1,2-ETHANEDIOL, 2-{(3M)-3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol, Bromodomain-containing protein 4, ... | 著者 | Sheriff, S. | 登録日 | 2022-05-09 | 公開日 | 2022-08-17 | 最終更新日 | 2023-10-18 | 実験手法 | X-RAY DIFFRACTION (1.685 Å) | 主引用文献 | Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties. Acs Med.Chem.Lett., 13, 2022
|
|
3ENS
 
 | |
2H5E
 
 | |
7MCF
 
 | CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-6-fluoro-5-[(S)-(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol | 分子名称: | 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-6-fluoro-5-[(S)-(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol, Bromodomain-containing protein 4 | 著者 | Sheriff, S. | 登録日 | 2021-04-02 | 公開日 | 2021-05-26 | 最終更新日 | 2023-10-18 | 実験手法 | X-RAY DIFFRACTION (2.19 Å) | 主引用文献 | Development of BET inhibitors as potential treatments for cancer: A search for structural diversity. Bioorg.Med.Chem.Lett., 44, 2021
|
|
8IIU
 
 | anti-VEGF nanobody | 分子名称: | SULFATE ION, anti-VEGF nanobody | 著者 | Qian, F, Zhu, S.Q. | 登録日 | 2023-02-24 | 公開日 | 2023-12-27 | 最終更新日 | 2024-10-23 | 実験手法 | X-RAY DIFFRACTION (1.27 Å) | 主引用文献 | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration. Bioeng Transl Med, 8, 2023
|
|
8IJZ
 
 | anti-VEGF mutant | 分子名称: | anti-VEGF nanobody | 著者 | Qian, F, Zhu, S.Q. | 登録日 | 2023-02-28 | 公開日 | 2023-12-27 | 最終更新日 | 2024-10-09 | 実験手法 | ELECTRON CRYSTALLOGRAPHY (2.1 Å) | 主引用文献 | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration. Bioeng Transl Med, 8, 2023
|
|
8IJS
 
 | anti-VEGF nanobody mutant | 分子名称: | ZINC ION, anti-VEGF nanobody | 著者 | Qian, F, Zhu, S.Q. | 登録日 | 2023-02-28 | 公開日 | 2023-12-27 | 最終更新日 | 2024-10-09 | 実験手法 | X-RAY DIFFRACTION (1.752 Å) | 主引用文献 | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration. Bioeng Transl Med, 8, 2023
|
|
8DY2
 
 | Crystal Structure of spFv GLK1 | 分子名称: | SULFATE ION, spFv GLK1 LH | 著者 | Luo, J, Boucher, L.E. | 登録日 | 2022-08-03 | 公開日 | 2023-05-03 | 最終更新日 | 2024-10-16 | 実験手法 | X-RAY DIFFRACTION (1.65 Å) | 主引用文献 | "Stapling" scFv for multispecific biotherapeutics of superior properties. Mabs, 15, 2023
|
|
8DY4
 
 | |
8DY0
 
 | |
8DY5
 
 | |
8DY1
 
 | |
8DY3
 
 | |
4FRS
 
 | |
7MP5
 
 | |